Professor Roger Kai-cheong NGAN

Clinical Professor
Chair of Specialty for Oncology, Gleneagles HK Hospital

  • MBBS (HK), LRCP (Lond), MRCS (Eng), DMRT (UK), FFRRCS(I), FRCR, FHKCR, FHKAM (Radiology)
Short Biography
Prof Roger Ngan is currently the Clinical Professor of the Department of Clinical Oncology, The University of Hong Kong. He is also the Honorary Consultant of the Departments of Clinical Oncology, Queen Mary Hospital and Queen Elizabeth Hospital of Hong Kong. He has worked for the past 5 years as the Chief of Service in the Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, and the Director of the Hong Kong Cancer Registry of the Hong Kong Hospital Authority. He is also currently an Adjunct Professor in Department of Health Technology and Informatics, Hong Kong Polytechnic University.

Prof Ngan is a specialist in clinical oncology who has special interests in the clinical research of multimodality management of various cancers including head and neck cancer, breast cancer, gynaecological cancers, and musculo-skeletal cancers. He is the clinical supervisor of translational cancer research in the Cancer Research Laboratory at Queen Elizabeth Hospital, and has published more than 90 articles in peer-reviewed journals and book chapters.

He is the current President of the Hong Kong Breast Oncology Group, Deputy Chief Editor of the Hong Kong Journal of Radiology, and a member of the Executive Management Council of the Hong Kong Center for NPC Research, Asian Sarcoma Consortium, and Scientific Advisory Committee of the State Key Laboratory in Oncology in South China at The Chinese University of Hong Kong. Prof Ngan has also made significant contributions to the cancer services in the public sector in Hong Kong, as a member of the Central Coordinating Committee in Clinical Oncology (Hospital Authority), the Central Committee of Cancer Services (Hospital Authority), the Cancer Coordinating Committee (CCC) of Bureau of Food and Hygiene (HKSAR Government), Cancer Expert Working Group on cancer prevention & screening of the CCC (HKSAR Government), and the Colorectal Cancer Screening Pilot Program Task Group of Department of Health (HKSAR Government).
Research Interests
Breast cancers, Head and Neck cancers, Gynaecological cancers, Soft tissue and Bone sarcomas, Brachytherapy and TomoTherapy
Selected Publications

Book and chapter

Ng WT, Ngan RKC, Chan OSH, Sze HCK, Chan JYW, Lee AWM. Management of nasopharyngeal carcinoma. In: Head and Neck Cancer: Multimodality Management. 2nd edition. J. Bernier (Ed). Springer, 2015.

Peer-reviewed journals

  • Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, Lee VHF, Tung SY, Chan ATC, Sze HCK, Cheng ACK, Lee AWM, Kwong DLW, Tam AHP. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16-21.3.


  • Ng WT, Ngan RKC, Kwong DLW, Tung SY, Yuen KT, Kam MKM, Sze HCK, Yiu HHY, Chan LLK, Lung ML, Lee AWM. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(3):630-638.


  • Dai W, Zheng H, Cheung AK, Tang CS, KO JM, Wong BW, Leong MM, Sham PC, Cheung F, Kwong DL, Ngan RK, Ng WT, Yau CC, Pan J, Peng X, Tung S, Zhang Z, Ji M, Chiang AK, Lee AW, Lee VH, Lam KO, Au KH, Cheng HC, Yiu HH, Lung ML. Whole-exome sequencing identifies MSTIR as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 2016;113(12):3317-22.


  • Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan OS, Choi H, Chappell R. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrentadjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328-38.


  • Lee FK, Yip CW, Cheung FC, Leung AK, Chau RM, Ngan RK. Dosimetric difference amongst 3 techniques: TomoTherapy, sliding-window intensity- modulated radiotherapy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC). Med Dosim. 2014; 39(1):44-9.


  • Chan OS, Ngan RK. Individualized treatment in stage IVC nasopharyngeal carcinoma. Oral Oncol. 2014;50(9):791-7.


  • Ng RH, Ngan R, Wei WI, Gullane PJ, Phillips J. Trans-oral brush biopsies and quantitative PCR for EBV DNA detection and screening of nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2014;150(4):602-9.


  • Ngan R, Wang E, Porter D, Desai J, Prayogo N, Devi B, Quek R. Soft-tissue sarcomas in the Asia-Pacific region: a systematic review. Asian Pac J Cancer Prev. 2013;14(11):6821-32.


  • Lewin J, Puri A, Quek R, Ngan R, Alcasabas AP, Wood D, Thomas D. Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e562-70.


  • Cho WC, Yip TT, Ngan RK. Yip TT, Podust VN, Yip C, Yiu HH, Yip V, Cheng WW, Ma VW, Law SC. ProteinChip array profiling for identification of disease- and chemotherapy associated-biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007;53(2):241-50.


  • Ngan RK, Wong RK, Tang FN, Tang DL. Curative radiotherapy for early cancers of the lip, buccal mucosa, and nose--a simple interstitial brachytherapy technique employing angiocatheters as carriers for Iridium-192 wire implants. Hong Kong Med J. 2005;11(5):351-9.


  • Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O'Sullivan B, Pang ES, O SK, Au GK, Lau JT; Hong Kong Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23(28):6966-75.


  • Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, Hui EP, Yiu HY, Yeo W, Cheung FY, Yu KH, Chiu KW, Chan DT, Mok TS, Yau S, Yuen KT, Mo FK, Lai MM, Ma BB, Kam MK, Leung TW, Johnson PJ, Choi PH, Zee BC. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536-9.


  • Ngan RK, Yip TT, Cheng WW, Chan JK, Cho WC, Ma VW, Wan KK, Au JS, Law CK Clinical role of circulating Epstein-Barr virus DNA as a tumor marker inlymphoepithelioma-like carcinoma of the lung. Ann N Y Acad Sci. 2004;1022:263-70.


  • Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, Kwok CH, Chiu CY, Au SK, Foo W, Law CK, Tse KC. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13(8):1252-8.


  • Ngan RK, Yip TT, Cheng WW, Chan JK, Cho WC, Ma VW, Wan KK, Au SK, Law CK, Lau WH. Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. Clin Cancer Res. 2002;8(4):986-94.


  • Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, Lai M, Kwan WH, Choi P, Johnson PJ. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002 Apr 15;20(8):2038-44.


  • Ngan RK, Yiu HH, Cheng HK, Chan JK, Sin VC, Lau WH. Central nervous system metastasis from nasopharyngeal carcinoma: a report of two patients and a review of the literature. Cancer. 2002 Jan 15,94(2):398-405.


  • Ngan RK, Lau WH, Yip TT, Cho WC, Cheng WW, Lim CK, Wan KK, Chu E, Joab I, Grunewald V, Poon YF, Ho JH. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann NY Acad Sci. 2001;945:73-9.